NCT01192022View on ClinicalTrials.gov

TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

PHASE3CompletedINTERVENTIONAL

Enrollment

253

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Hemorrhage

Interventions

BIOLOGICAL

TachoSil®

Intraoperative application as secondary hemostatic treatment

DEVICE

Surgicel® Original

Intraoperative application as secondary hemostatic treatment

Trial Locations (17)

Unknown

Los Angeles

Washington D.C.

Chicago

Louisville

New Orleans

Burlington

St Louis

Newark

New York

Charlotte

Cincinnati

Philadelphia

Charleston

Memphis

Nashville

Charlottesville

Madison

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY